Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proof of concept: performance testing in models.

W A Craig1

  • 1University of Wisconsin and the William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA. wac@medicine.wisc.edu

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|February 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Antimicrobial agents and chemotherapy·2014
Same author

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Antimicrobial agents and chemotherapy·2013
Same author

In vivo pharmacodynamics of new lipopeptide MX-2401.

Antimicrobial agents and chemotherapy·2010
Same author

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2008
Same author

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Antimicrobial agents and chemotherapy·2006
Same author

Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2005
Same journal

Impact of low-dose chest CT and multiplex PCR on antibiotic usage for community-acquired pneumonia: multicentre prospective controlled before-after study with cluster randomisation (CAP-NEXT study).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Clinical Microbiology and Infection: how did we do in 2025?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Automate the work, not the decision: aligning expectations for AI in clinical microbiology.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Doxycycline prophylaxis and gonococcal resistance: reassurance, residual signals, and the case for surveillance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Oral metronidazole versus clindamycin to treat bacterial vaginosis in pregnancies at risk for preterm labor.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same journal

Efficacy and safety of a radiographic severity-stratified all-oral short treatment regimen for multidrug/rifampicin-resistant tuberculosis in China: An open-label, multi-center,randomized controlled, non-inferiority trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
See all related articles

New amoxicillin/clavulanate formulations, designed using pharmacokinetic/pharmacodynamic (PK/PD) principles, show enhanced efficacy against drug-resistant Streptococcus pneumoniae. The 2000/125 mg twice daily adult formulation offers improved treatment options for respiratory tract infections.

Area of Science:

  • Microbiology and Infectious Diseases
  • Pharmacology and Pharmaceutical Sciences

Background:

  • Current amoxicillin/clavulanate formulations face challenges with increasing penicillin-nonsusceptible Streptococcus pneumoniae strains.
  • Drug resistance necessitates the development of novel antimicrobial strategies and optimized dosing regimens.

Purpose of the Study:

  • To design and evaluate new oral amoxicillin/clavulanate formulations utilizing pharmacokinetic/pharmacodynamic (PK/PD) principles.
  • To assess the efficacy of enhanced formulations against Streptococcus pneumoniae, including drug-resistant strains.

Main Methods:

  • Development of a pediatric formulation (90/6.4 mg/kg/day) and an enhanced adult formulation (2000/125 mg twice daily) based on PK/PD targets (35-40% time above MIC).
  • In vitro kinetic models and a rat pneumonia model were used to simulate human pharmacokinetics and assess efficacy.

Related Experiment Videos

  • Comparative efficacy analysis against conventional amoxicillin/clavulanate, azithromycin, and levofloxacin.

    • Main Results:

    • The amoxicillin/clavulanate 2000/125 mg twice daily formulation demonstrated high efficacy against S. pneumoniae strains with amoxicillin MICs of 4 or 8 mg/L.
    • This enhanced formulation showed significantly greater efficacy than the conventional 875/125 mg formulation, azithromycin, and levofloxacin against strains with MICs of 4 mg/L.
    • Against strains with amoxicillin MICs of 8 mg/L, the 2000/125 mg formulation exhibited superior or comparable efficacy to conventional amoxicillin/clavulanate, azithromycin, and levofloxacin.

    Conclusions:

    • The amoxicillin/clavulanate 2000/125 mg twice daily formulation, guided by PK/PD principles, offers a promising therapeutic option for respiratory tract infections.
    • This enhanced formulation provides improved coverage against penicillin-nonsusceptible Streptococcus pneumoniae compared to existing treatments.
    • The study highlights the successful application of PK/PD modeling in optimizing antimicrobial drug design and efficacy.